Related Experiment Videos
[Hypolipidemic effect of gevilon]
Kardiologiia
|January 1, 1993
Summary
Gevilon demonstrates significant hypolipidemic effects, effectively lowering cholesterol and triglycerides in patients with coronary heart disease and hypertension. This drug shows promise for managing lipid disorders and improving cardiovascular health.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism
- Clinical Therapeutics
Context:
- Investigates the therapeutic potential of Gevilon, a novel hypolipidemic agent.
- Focuses on patients with coronary heart disease and severe lipid metabolic disturbances.
- Addresses the clinical need for effective lipid-lowering therapies.
Purpose:
- To evaluate the hypolipidemic efficacy and tolerability of Gevilon.
- To assess Gevilon's impact on lipid profiles, including total cholesterol, beta-cholesterol, triglycerides, and alpha-cholesterol.
- To determine the optimal application of Gevilon in managing dyslipoproteinemia.
Summary:
- Gevilon treatment in 53 patients with coronary heart disease and hypertension resulted in significant reductions in total cholesterol, beta-cholesterol, and triglycerides.
- The drug effectively increased alpha-cholesterol levels and normalized the atherogenicity coefficient, indicating improved lipid profiles.
- Gevilon exhibited its most pronounced hypolipidemic effects in patients with Type IIb dyslipoproteinemia.
- The drug was well-tolerated and suitable for combination therapy with existing treatments for coronary heart disease and hypertension.
Impact:
- Gevilon represents a promising therapeutic option for managing hyperlipidemia in patients with cardiovascular conditions.
- Clinical findings support Gevilon's role in improving lipid profiles and potentially reducing cardiovascular risk.
- The drug's favorable tolerability profile enhances its clinical utility in complex therapeutic regimens.